Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Mar;32(2):302-308.
doi: 10.3904/kjim.2016.199. Epub 2016 Dec 13.

Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment

I-Nae Park  1 , Tae Sun Shim  2
Affiliations
Comparative Study

Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment

I-Nae Park et al. Korean J Intern Med. 2017 Mar.

Abstract

Background/aims: The usefulness of interferon-γ release assays (IGRAs) in monitoring to responses to anti-tuberculosis (TB) treatment is controversial. We compared the results of two IGRAs before and after anti-TB treatment in same patients with active TB.

Methods: From a retrospective review, we selected patients with active TB who underwent repeated QuantiFERON-TB Gold (QFN-Gold, Cellestis Limited) and T-SPOT.TB (Oxford Immunotec) assays before and after anti-TB treatment with first-line drugs. Both tests were performed prior to the start of anti-TB treatment or within 1 week after the start of anti-TB treatment and after completion of treatment.

Results: A total of 33 active TB patients were included in the study. On the QFN-Gold test, at baseline, 23 cases (70%) were early secreted antigenic target 6-kDa protein 6 (ESAT-6) or culture filtrate protein 10 (CFP-10) positive. On the T-SPOT. TB test, at baseline, 31 cases (94%) were ESAT-6 or CFP-10 positive. Most of patients remained both test-positive after anti-TB treatment. Although changes in interferon-γ release responses over time were highly variable in both tests, there was a mean decline of 27 and 24 spot-forming counts for ESAT-6 and CFP-10, respectively on the T-SPOT.TB test (p < 0.05 for all).

Conclusions: Although limited by the small number of patients and a short-term follow-up, there was significant decline in the quantitative result of the T-SPOT. TB test with treatment. However, both commercial IGRAs may not provide evidence regarding the cure of disease in Korea, a country where the prevalence of TB is within the intermediate range.

Keywords: Interferon-gamma release tests; Therapeutics; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1.
Figure 1.
Change in the QuantiFERON-TB Gold (QFN-Gold, Cellestis Limited) test results for patients with active tuberculosis (TB) before and after anti-TB treatment. TST, tuberculin skin test; PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis.
Figure 2.
Figure 2.
Change in the T-SPOT.TB (Oxford Immunotec) test results for patients with active tuberculosis (TB) before and after anti-TB treatment. TST, tuberculin skin test; PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis.
Figure 3.
Figure 3.
Paired before and after treatment quantitative interferon-γ (IFN-γ) level on the QuantiFERON-TB Gold (QFN-Gold, Cellestis Limited) test using (A) early secreted antigenic target 6-kDa protein 6 and (B) culture filtrate protein 10.
Figure 4.
Figure 4.
Paired before and after treatment quantitative interferon-γ level in on the T-SPOT.TB (Oxford Immunotec) test using (A) early secreted antigenic target 6-kDa protein 6 and (B) culture filtrate protein 10.
See this image and copyright information in PMC

References

    1. World Health Organization . Global Tuberculosis Report 2015. Geneva: World Health Organization; 2015.
    1. World Health Organization . Treatment of Tuberculosis: Guidelines for National Programmes. 3rd ed. Geneva: World Health Organization; 2003.
    1. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep. 2010;59:1–25. - PubMed
    1. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet. 2004;364:2196–2203. - PubMed
    1. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49–55. - PubMed

Publication types

Substances

LinkOut - more resources